期刊文献+

奥斯替尼合成路线图解 被引量:1

Synthetic Routes for Osimertinib
下载PDF
导出
摘要 综述了现有的奥斯替尼的合成方法,并针对不同的合成工艺进行了研究与分析,提出适合工业化生产的路线。以4-氟-2-甲氧基-5-硝基苯胺(2)为起始原料经过Boc保护、亲核取代、氢化还原、酰化、脱保护一系列反应得到关键中间体N-(5-氨基-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺(7),最后以吲哚(8)为起始原料通过甲基化、亲核取代、环合制得目标化合物1。该路线简单易操作,成本较低,收率较高,适宜工业化生产。 The various synthetic methods for osimertinib were summarized and analyzed to develop a suitable industrial synthetic routes. The most valuable ways for commercial scale production to obtain the title compound 1 was using indole (8) and 4-fluoro-2-methoxy-5-nitroaniline (2) as the starting materials.
出处 《精细化工中间体》 CAS 2017年第2期21-24,共4页 Fine Chemical Intermediates
关键词 奥斯替尼 表皮生长因子受体 不可逆抑制剂 非小细胞肺癌 合成路线图解 osimertinib epidermal growth factor receptor , irreversible inhibitors non-small cell lung cancer,synthetic routes
  • 相关文献

参考文献3

二级参考文献26

  • 1AstraZeneca Inc. Tagrisso?: US prescribing information [EB/OL].(2015-11-13) [2015-12-30]. http://www.accessdata.fda.gov.
  • 2Shien K, Yamamoto H, Soh J, et al. Drug Resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer[J]. Acta Medica Okayama, 2014, 68(4): 191-200.
  • 3Cross D A, Ashton S E, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[J]. Cancer Discov, 2014, 4(9): 1046-1061.
  • 4Vallée A, Audigier-Valette C, Herbreteau G, et al. Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation[J]. Lung Cancer, 2016(91): 73-74.
  • 5Shepherd F A, José R P, Tudor C, et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Engl J Med, 2005, 353(2): 1656-1658.
  • 6Sequist L V, James Chih-Hsin Y, Nobuyuki Y, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J]. J Clin Oncol, 2013, 31(27):3327-3334.
  • 7US FDA.FDA approves new pill to treat certain patients with non-small cell lung cancer[EB/OL].[2015-11-13].http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm.
  • 8BUTTERWORTH S,FINLAY M R V,WARD R A,et al.2-(2,4,5-Substituted aniline)pyrimidine compounds:8946235[P].2015-02-03.
  • 9布特沃斯S,芬莱M R V,瓦德R A,等.2-(2,4,5-取代苯胺)嘧啶衍生物作为EGFR调谐子用于治疗癌症:103702990[P]2015-09-09.
  • 10FINLAY M R V,ANDERTON M,ASHTON S,et al.Discovery of a potent and selective EGFR inhibitor(AZD9291)of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor[J].J Med Chem,2014,57(20):8249-8267.

共引文献22

同被引文献8

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部